Compugen Ltd

Compugen Ltd. a clinical-stage therapeutic discovery and development company researches develops and commercializes therapeutic and product candidates in Israel the United States and Europe. The company's immuno-oncology pipeline consists of COM701 an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902 a therapeutic antibody targeting TIGIT which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig a novel anti-TIGIT/PD-1 bispecific antibody which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503 high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research development and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon Israel.